09.23.13
Robert C. Buhrmaster, chairman of SurModics Inc., will step down from his position in February next year. Taking his place will be Scott R. Ward, who currently serves on the company board of directors.
“On behalf of SurModics, I want to thank Bob for his outstanding leadership since 2008, when he joined our board,” said Gary Maharaj, president and CEO of SurModics. “He has played a significant role in positioning the company for future growth, and we wish him all the best. We also look forward to welcoming Scott to his new role of board chair in February. As we pursue our business strategy to grow SurModics’ core businesses and expand beyond the core, Scott’s extensive medical device and business experience will be invaluable.”
“I am confident that this is the right time to pass the baton to a new board chair,” said Buhrmaster. “I believe that Scott is the right person to guide SurModics to new levels of growth in its medical device and in vitro diagnostics businesses. I am proud of the company’s accomplishments and excited to watch its future progress.”
Ward has been a Director of SurModics since 2010. He is a managing director at SightLine Partners and the Founder of Raymond Holdings. Ward has more than 30 years of experience in the healthcare industry, including 15 years as a senior operating business leader, most recently at Medtronic, where he served as senior vice president and president of its cardiovascular business. Previously, Ward was Medtronic’s senior vice president and president of the neurological and diabetes businesses; vice president and general manager of the Medtronic drug delivery business; and director of Medtronic Neuroventures. Ward serves on the boards of Creganna-Tactx Medical (as chairman), Impedimed, and several other early stage private companies.
SurModics provides surface modification technologies and in vitro diagnostic chemical components, and is based in Eden Prairie, Minn.
“On behalf of SurModics, I want to thank Bob for his outstanding leadership since 2008, when he joined our board,” said Gary Maharaj, president and CEO of SurModics. “He has played a significant role in positioning the company for future growth, and we wish him all the best. We also look forward to welcoming Scott to his new role of board chair in February. As we pursue our business strategy to grow SurModics’ core businesses and expand beyond the core, Scott’s extensive medical device and business experience will be invaluable.”
“I am confident that this is the right time to pass the baton to a new board chair,” said Buhrmaster. “I believe that Scott is the right person to guide SurModics to new levels of growth in its medical device and in vitro diagnostics businesses. I am proud of the company’s accomplishments and excited to watch its future progress.”
Ward has been a Director of SurModics since 2010. He is a managing director at SightLine Partners and the Founder of Raymond Holdings. Ward has more than 30 years of experience in the healthcare industry, including 15 years as a senior operating business leader, most recently at Medtronic, where he served as senior vice president and president of its cardiovascular business. Previously, Ward was Medtronic’s senior vice president and president of the neurological and diabetes businesses; vice president and general manager of the Medtronic drug delivery business; and director of Medtronic Neuroventures. Ward serves on the boards of Creganna-Tactx Medical (as chairman), Impedimed, and several other early stage private companies.
SurModics provides surface modification technologies and in vitro diagnostic chemical components, and is based in Eden Prairie, Minn.